close

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. The company's drug candidates in Phase II clinical trials include Archexin, a inhibitor of the protein kinase Akt for the treatment of renal cell carcinoma and pancreatic cancer; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a CNS-based sexual dysfunction drug product for the treatment of sexual dysfunction. Its pre-clinical pipeline products include RX-0201-Nano, a nanoliposomal anti-cancer Akt-1 inhibitor; RX-0047-Nano, a nanoliposomal anti-cancer HIF-1 alpha inhibitor; Nano-polymer anticancer drugs; RX-0183, small molecule targeted anticancer drug candidate; RX-5902, small molecule microtubule inhibitor anticancer drug candidate; and RX-3117, small molecule anti-metabolite nucleoside anticancer drug candidate. Rexahn Pharmaceuticals has collaboration and license arrangements with UPM Pharmaceuticals, Inc.; Korean Research Institute of Bioscience and Biotechnology; Ewha Womans University; Korea Research Institute of Chemical Technology; The University of Maryland; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Formatech, Inc. The company is based in Rockville, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.49
Volume	68615
Volume Avg	185395
52 Week High	1.53
52 Week Low	0.34
PE	N/A
PE (group average)	N/A
EPS Year	-0.16
EPS change Q/Q	-66.67%
EPS change Q/Q Yr ago	-54.55%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-7.69%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	0.11
Divident Annual	0.00
Dividend Yield	0%